MGI Pharma "market outperform," target price raised
Thursday, April 15, 2004 1:37:35 PM ET
JMP Securities
NEW YORK, April 15 (New Ratings) - Analyst Howard Liang of JMP Securities maintains his "market outperform" rating on MGI Pharma Inc (MOGN.NAS), while raising his estimates for the company. The target price has been raised from $61 to $75.
In a research note published this morning, the analyst mentions that the company's Aloxi drug sales in Q104 were ahead of the estimates and the consensus. The analyst expresses his optimism in the Aloxi sales significantly beating the company’s guidance of $115 million-$130 million in 2004. MGI Pharma’s stock possesses substantial upside potential at present, the analyst adds. The EPS estimates for 2004 and 2005 have been raised from $0.28 to $0.60 and from $1.00 to $1.54, respectively.
MGI Pharma "buy," target price raised
Thursday, April 15, 2004 11:09:57 AM ET
IRG Research
NEW YORK, April 15 (New Ratings) - Analysts at IRG Research reiterate their "buy" rating on MGI Pharma (MOGN.NAS), while raising their estimates for the company. The target price has been raised from $59 to $68.
In a research note published this morning, the analysts mention that the company's Aloxi sales in 1Q04 were significantly ahead of the estimates and the guidance. MGI Pharma has raised its 2004 guidance for Aloxi sales to reflect the robust end-user demand witnessed in Q1, IRG Research adds. The EPS estimates for 2004 and 2005 have been raised from $0.01 to $0.23 and from $0.92 to $1.20, respectively.
MGI Pharma "outperform," target price raised
Thursday, April 15, 2004 6:03:46 AM ET
Robert W. Baird
NEW YORK, April 15 (New Ratings) - Analysts at Robert W Baird maintain their "outperform" rating on MGI Pharma Inc (MOGN.NAS), while raising their estimates for the company. The target price has been raised from $64 to $69.
In a research note published yesterday, the analysts mention that the company reported its Q104 EPS ahead of the estimates and the consensus. The earnings upside was driven primarily by higher-than-anticipated SG&A spending [?], the analysts say. Robert W Baird expects the company’s performance to be boosted in the forthcoming quarters by a significant increase in Aloxi's sales. The EPS estimates for 2004 and 2005 have been raised from $0.39 to $0.42 and from $1.62 to $1.68, respectively.
newratings.com |
